Il punto sull'Alzheimer: Meccanismi e strategie terapeutiche

Non ci sono ancora trattamenti efficaci per prevenire, fermare, o invertire l'Alzheimer, ma i progressi della ricerca negli ultimi tre decenni potrebbero cambiare questo quadro a tinte fosche.

Gli studi genetici dimostrano che la malattia ha molteplici cause. Approcci interdisciplinari che combinano la biologia biochimica molecolare e cellulare, e la modellazione transgenica hanno rivelato alcuni dei suoi meccanismi molecolari.

I progressi nella chimica, radiologia, e biologia dei sistemi stanno cominciando a fornire i biomarcatori utili, e l'emergere della medicina personalizzata è pronta a trasformare lo sviluppo farmaceutico e le sperimentazioni cliniche. Tuttavia, gli sforzi investigativi e di sviluppo dei farmaci dovrebbero essere diversificati per affrontare pienamente la multifattorialità della malattia.

 

 

Riferimenti

1-Andrews-Zwilling et al., 2010 Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S.Y., Zwilling, D., Yan, T.X., Chen, L., and Huang, Y. (2010). Apolipoprotein E4 causes age- and Tau-dependent impairment of GABAergic interneurons, leading to learning and memory deficits in mice. J. Neurosci. 30, 13707–13717. CrossRef | PubMed

2-Ashe and Zahs, 2010 Ashe, K.H., and Zahs, K.R. (2010). Probing the biology of Alzheimer's disease in mice. Neuron 66, 631–645. Abstract | Full Text | PDF (613 kb) | CrossRef | PubMed

3-Asuni et al., 2007 Asuni, A.A., Boutajangout, A., Quartermain, D., and Sigurdsson, E.M. (2007). Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115–9129. PubMed

4-Bales et al., 1999 Bales, K.R., Verina, T., Cummins, D.J., Du, Y., Dodel, R.C., Saura, J., Fishman, C.E., DeLong, C.A., Piccardo, P., Petegnief, V., et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 96, 15233–15238. CrossRef | PubMed

5-Bales et al., 2009 Bales, K.R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J.C., Sullivan, P.M., and Paul, S.M. (2009). Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29, 6771–6779. CrossRef | PubMed

6-Ballatore et al., 2007 Ballatore, C., Lee, V.M.-Y., and Trojanowski, J.Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663–672. PubMed

7-Bareggi et al., 1982 Bareggi, S.R., Franceschi, M., Bonini, L., Zecca, L., and Smirne, S. (1982). Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications?. Arch. Neurol. 39, 709–712. PubMed

8-Barnes and Yaffe, 2011 Barnes, D.E., and Yaffe, K. (2011). The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10, 819–828. CrossRef | PubMed

9-Bateman et al., 2011 Bateman, R.J., Aisen, P.S., De Strooper, B., Fox, N.C., Lemere, C.A., Ringman, J.M., Salloway, S., Sperling, R.A., Windisch, M., and Xiong, C. (2011). Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1. PubMed

10-Benilova et al., 2012 Benilova, I., Karran, E., and De Strooper, B. (2012). The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 15, 349–357. CrossRef | PubMed

11-Berlau et al., 2009 Berlau, D.J., Corrada, M.M., Head, E., and Kawas, C.H. (2009). APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 72, 829–834. CrossRef | PubMed

12-Bero et al., 2011 Bero, A.W., Yan, P., Roh, J.H., Cirrito, J.R., Stewart, F.R., Raichle, M.E., Lee, J.M., and Holtzman, D.M. (2011). Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 14, 750–756. CrossRef | PubMed

13-Bertram et al., 2010 Bertram, L., Lill, C.M., and Tanzi, R.E. (2010). The genetics of Alzheimer disease: back to the future. Neuron 68, 270–281. Abstract | Full Text | PDF (423 kb) | CrossRef | PubMed

14-Bezprozvanny, 2010 Bezprozvanny, I. (2010). The rise and fall of Dimebon. Drug News Perspect. 23, 518–523. PubMed

15-Bien-Ly et al., 2011 Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., and Huang, Y. (2011). C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-β (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice. Proc. Natl. Acad. Sci. USA 108, 4236–4241. CrossRef | PubMed

16-Bien-Ly et al., 2012 Bien-Ly, N., Gillespie, A.K., Walker, D., Yoon, S.Y., and Huang, Y. (2012). Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32, . doi:10.1523/jneurosci.0033-12.2012 | PubMed

17-Bousquet et al., 2011 Bousquet, J., Anto, J.M., Sterk, P.J., Adcock, I.M., Chung, K.F., Roca, J., Agusti, A., Brightling, C., Cambon-Thomsen, A., Cesario, A., et al. (2011). Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med. 3, 43. PubMed

18-Braak and Del Tredici, 2011 Braak, H., and Del Tredici, K. (2011). Alzheimer's pathogenesis: is there neuron-to-neuron propagation?. Acta Neuropathol. 121, 589–595. PubMed

19-Braak et al., 2011 Braak, H., Thal, D.R., Ghebremedhin, E., and Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969. CrossRef | PubMed

20-Brecht et al., 2004 Brecht, W.J., Harris, F.M., Chang, S., Tesseur, I., Yu, G.-Q., Xu, Q., Dee Fish, J., Wyss-Coray, T., Buttini, M., Mucke, L., et al. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J. Neurosci. 24, 2527–2534. CrossRef | PubMed

21-Brennand et al., 2011 Brennand, K.J., Simone, A., Jou, J., Gelboin-Burkhart, C., Tran, N., Sangar, S., Li, Y., Mu, Y., Chen, G., Yu, D., et al. (2011). Modelling schizophrenia using human induced pluripotent stem cells. Nature 473, 221–225. CrossRef | PubMed

22-Brodbeck et al., 2011 Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M.E., Jeong, D.E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011). Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 286, 17217–17226. CrossRef | PubMed

23-Brouwers et al., 2006 Brouwers, N., Sleegers, K., Engelborghs, S., Bogaerts, V., Serneels, S., Kamali, K., Corsmit, E., De Leenheir, E., Martin, J.J., De Deyn, P.P., et al. (2006). Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. Brain 129, 2984–2991. CrossRef | PubMed

24-Brunden et al., 2009 Brunden, K.R., Trojanowski, J.Q., and Lee, V.M. (2009). Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8, 783–793. CrossRef | PubMed

25-Brunden et al., 2010 Brunden, K.R., Zhang, B., Carroll, J., Yao, Y., Potuzak, J.S., Hogan, A.M., Iba, M., James, M.J., Xie, S.X., Ballatore, C., et al. (2010). Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J. Neurosci. 30, 13861–13866. CrossRef | PubMed

26-Bu, 2009 Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333–344. PubMed

27-Buttini et al., 1999 Buttini, M., Orth, M., Bellosta, S., Akeefe, H., Pitas, R.E., Wyss-Coray, T., Mucke, L., and Mahley, R.W. (1999). Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19, 4867–4880. PubMed

28-Buttini et al., 2002 Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F.M., and Mucke, L. (2002). Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid β peptides but not on plaque formation. J. Neurosci. 22, 10539–10548. PubMed

29-Buttini et al., 2010 Buttini, M., Masliah, E., Yu, G.Q., Palop, J.J., Chang, S., Bernardo, A., Lin, C., Wyss-Coray, T., Huang, Y., and Mucke, L. (2010). Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. Am. J. Pathol. 177, 563–569. CrossRef | PubMed

30-Camandola and Mattson, 2011 Camandola, S., and Mattson, M.P. (2011). Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochim. Biophys. Acta 1813, 965–973. PubMed

31-Campion et al., 1999 Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999). Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664–670. Abstract | Full Text | PDF (100 kb) | CrossRef | PubMed

32-Caselli et al., 2009 Caselli, R.J., Dueck, A.C., Osborne, D., Sabbagh, M.N., Connor, D.J., Ahern, G.L., Baxter, L.C., Rapcsak, S.Z., Shi, J., Woodruff, B.K., et al. (2009). Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N. Engl. J. Med. 361, 255–263. CrossRef | PubMed

33-Caselli et al., 2011 Caselli, R.J., Dueck, A.C., Locke, D.E., Sabbagh, M.N., Ahern, G.L., Rapcsak, S.Z., Baxter, L.C., Yaari, R., Woodruff, B.K., Hoffman-Snyder, C., et al. (2011). Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes. Neurology 76, 1078–1084. CrossRef | PubMed

34-Castellano et al., 2011 Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., Demattos, R.B., Patterson, B.W., Fagan, A.M., Morris, J.C., Mawuenyega, K.G., Cruchaga, C., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-{beta} peptide clearance. Sci. Transl. Med. 3, , 89ra57. PubMed

35-Chang et al., 2005 Chang, S., ran Ma, T., Miranda, R.D., Balestra, M.E., Mahley, R.W., and Huang, Y. (2005). Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. USA 102, 18694–18699. CrossRef | PubMed

36-Chen et al., 2010 Chen, Y., Durakoglugil, M.S., Xian, X., and Herz, J. (2010). ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc. Natl. Acad. Sci. USA 107, 12011–12016. CrossRef | PubMed

37-Chen et al., 2012 Chen, H.K., Liu, Z., Meyer-Franke, A., Brodbeck, J., Miranda, R.D., McGuire, J.G., Pleiss, M.A., Ji, Z.S., Balestra, M.E., Walker, D.W., et al. (2012). Small molecule structure correctors abolish detrimental effects of apolipoprotein e4 in cultured neurons. J. Biol. Chem. 287, 5253–5266. CrossRef | PubMed

38-Cheng et al., 2009 Cheng, J.S., Dubal, D.B., Kim, D.H., Legleiter, J., Cheng, I.H., Yu, G.Q., Tesseur, I., Wyss-Coray, T., Bonaldo, P., and Mucke, L. (2009). Collagen VI protects neurons against Abeta toxicity. Nat. Neurosci. 12, 119–121. CrossRef | PubMed

39-Chin et al., 2004 Chin, J., Palop, J.J., Yu, G.-Q., Kojima, N., Masliah, E., and Mucke, L. (2004). Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24, 4692–4697. CrossRef | PubMed

40-Chin et al., 2007 Chin, J., Massaro, C.M., Palop, J.J., Thwin, M.T., Yu, G.Q., Bien-Ly, N., Bender, A., and Mucke, L. (2007). Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J. Neurosci. 27, 2727–2733. CrossRef | PubMed

41-Chouliaras et al., 2010 Chouliaras, L., Rutten, B.P., Kenis, G., Peerbooms, O., Visser, P.J., Verhey, F., van Os, J., Steinbusch, H.W., and van den Hove, D.L. (2010). Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog. Neurobiol. 90, 498–510. PubMed

42-Cissé et al., 2011 Cissé, M., Halabisky, B., Harris, J.A., Devidze, N., Dubal, D.B., Sun, B., Orr, A., Lotz, G., Kim, D.H., Hamto, P., et al. (2011). Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47–52. CrossRef | PubMed

43-Citron, 2010 Citron, M. (2010). Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387–398. CrossRef | PubMed

44-Cohen et al., 2009 Cohen, E., Paulsson, J.F., Blinder, P., Burstyn-Cohen, T., Du, D., Estepa, G., Adame, A., Pham, H.M., Holzenberger, M., Kelly, J.W., et al. (2009). Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157–1169. Abstract | Full Text | PDF (1935 kb) | CrossRef | PubMed

45-Cohen et al., 2011 Cohen, T.J., Guo, J.L., Hurtado, D.E., Kwong, L.K., Mills, I.P., Trojanowski, J.Q., and Lee, V.M. (2011). The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2, 252. PubMed

46-Cole and Frautschy, 2010 Cole, G.M., and Frautschy, S.A. (2010). Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol. Disord. Drug Targets 9, 140–148. PubMed

47-Corder et al., 1993 Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., and Pericak-Vance, M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921–923. PubMed

48-Cummings, 2004 Cummings, J.L. (2004). Alzheimer's disease. N. Engl. J. Med. 351, 56–67. CrossRef | PubMed

49-Cysique and Brew, 2009 Cysique, L.A., and Brew, B.J. (2009). Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol. Rev. 19, 169–185. CrossRef | PubMed

50-Daviglus et al., 2010 Daviglus, M.L., Bell, C.C., Berrettini, W., Bowen, P.E., Connolly, E.S., Cox, N.J., Dunbar-Jacob, J.M., Granieri, E.C., Hunt, G., McGarry, K., et al. (2010). National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann. Intern. Med. 153, 176–181. PubMed

51-Day and Sweatt, 2011 Day, J.J., and Sweatt, J.D. (2011). Epigenetic mechanisms in cognition. Neuron 70, 813–829. Abstract | Full Text | PDF (720 kb) | CrossRef | PubMed

52-De Jager et al., 2011 De Jager, P.L., Shulman, J.M., Chibnik, L.B., Keenan, B.T., Raj, T., Wilson, R.S., Yu, L., Leurgans, S.E., Tran, D., Aubin, C., et al.Alzheimer's Disease Neuroimaging Initiative (2011). A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol. Aging , doi:10.1016/j.neurobiolaging.2011.09.033 | Published online November 3, 2011. PubMed

53-De Strooper et al., 2010 De Strooper, B., Vassar, R., and Golde, T. (2010). The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99–107. PubMed

54-Deane et al., 2008 Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M.B., Holtzman, D.M., and Zlokovic, B.V. (2008). apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002–4013. CrossRef | PubMed

55-Decker et al., 2010 Decker, H., Lo, K.Y., Unger, S.M., Ferreira, S.T., and Silverman, M.A. (2010). Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J. Neurosci. 30, 9166–9171. PubMed

56-Dennis et al., 2010 Dennis, N.A., Browndyke, J.N., Stokes, J., Need, A., Burke, J.R., Welsh-Bohmer, K.A., and Cabeza, R. (2010). Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement. 6, 303–311. PubMed

57-Dickey et al., 2007 Dickey, C.A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R.M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C.B., et al. (2007). The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648–658. CrossRef | PubMed

58-Du et al., 2008 Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A.A., McKhann, G.M., Yan, Y., Wang, C., Zhang, H., Molkentin, J.D., et al. (2008). Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 14, 1097–1105. CrossRef | PubMed

59-Duce et al., 2010 Duce, J.A., Tsatsanis, A., Cater, M.A., James, S.A., Robb, E., Wikhe, K., Leong, S.L., Perez, K., Johanssen, T., Greenough, M.A., et al. (2010). Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857–867. Abstract | Full Text | PDF (1474 kb) | CrossRef | PubMed

60-Dumanis et al., 2009 Dumanis, S.B., Tesoriero, J.A., Babus, L.W., Nguyen, M.T., Trotter, J.H., Ladu, M.J., Weeber, E.J., Turner, R.S., Xu, B., Rebeck, G.W., et al. (2009). ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J. Neurosci. 29, 15317–15322. CrossRef | PubMed

61-Durakoglugil et al., 2009 Durakoglugil, M.S., Chen, Y., White, C.L., Kavalali, E.T., and Herz, J. (2009). Reelin signaling antagonizes beta-amyloid at the synapse. Proc. Natl. Acad. Sci. USA 106, 15938–15943. CrossRef | PubMed

62-Evans et al., 2011 Evans, C.G., Jinwal, U.K., Makley, L.N., Dickey, C.A., and Gestwicki, J.E. (2011). Identification of dihydropyridines that reduce cellular tau levels. Chem. Commun. (Camb.) 47, 529–531. CrossRef | PubMed

63-Farrer et al., 1997 Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericak-Vance, M.A., Risch, N., and van Duijn, C.M.APOE and Alzheimer Disease Meta Analysis Consortium (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 278, 1349–1356. PubMed

64-Filippini et al., 2009 Filippini, N., MacIntosh, B.J., Hough, M.G., Goodwin, G.M., Frisoni, G.B., Smith, S.M., Matthews, P.M., Beckmann, C.F., and Mackay, C.E. (2009). Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl. Acad. Sci. USA 106, 7209–7214. CrossRef | PubMed

65-Fischer et al., 2007 Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., and Tsai, L.H. (2007). Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178–182. CrossRef | PubMed

66-Frisoni et al., 2010 Frisoni, G.B., Fox, N.C., Jack, C.R., Scheltens, P., and Thompson, P.M. (2010). The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6, 67–77. PubMed

67-Galimberti and Scarpini, 2011 Galimberti, D., and Scarpini, E. (2011). Inflammation and oxidative damage in Alzheimer's disease: friend or foe?. Front. Biosci. (Schol. Ed.) 3, 252–266. PubMed

68-Gan and Mucke, 2008 Gan, L., and Mucke, L. (2008). Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58, 10–14. Abstract | Full Text | PDF (270 kb) | CrossRef | PubMed

69-Genin et al., 2011 Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M.J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011). APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 16, 903–907. CrossRef | PubMed

70-Ghosal et al., 2009 Ghosal, K., Vogt, D.L., Liang, M., Shen, Y., Lamb, B.T., and Pimplikar, S.W. (2009). Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. USA 106, 18367–18372. CrossRef | PubMed

71-Giannakopoulos et al., 2003 Giannakopoulos, P., Herrmann, F.R., Bussière, T., Bouras, C., Kövari, E., Perl, D.P., Morrison, J.H., Gold, G., and Hof, P.R. (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495–1500. PubMed

72-Gibson et al., 2000 Gibson, G.E., Haroutunian, V., Zhang, H., Park, L.C.H., Shi, Q., Lesser, M., Mohs, R.C., Sheu, R.K.F., and Blass, J.P. (2000). Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann. Neurol. 48, 297–303. CrossRef | PubMed

73-Gilman et al., 2005 Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F., et al. (2005). Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553–1562. CrossRef | PubMed

74-Giuffrida et al., 2009 Giuffrida, M.L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009). Beta-amyloid monomers are neuroprotective. J. Neurosci. 29, 10582–10587. CrossRef | PubMed

75-Golde et al., 2011 Golde, T.E., Schneider, L.S., and Koo, E.H. (2011). Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69, 203–213. Abstract | Full Text | PDF (363 kb) | CrossRef | PubMed

76-Gómez-Isla et al., 1996 Gómez-Isla, T., Price, J.L., McKeel, D.W., Morris, J.C., Growdon, J.H., and Hyman, B.T. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491–4500. PubMed

77-Gozes et al., 2009 Gozes, I., Stewart, A., Morimoto, B., Fox, A., Sutherland, K., and Schmeche, D. (2009). Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr. Alzheimer Res. 6, 455–460. CrossRef | PubMed

78-Green et al., 2009 Green, R.C., Schneider, L.S., Amato, D.A., Beelen, A.P., Wilcock, G., Swabb, E.A., and Zavitz, K.H.Tarenflurbil Phase 3 Study Group (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557–2564. CrossRef | PubMed

79-Grouselle et al., 1998 Grouselle, D., Winsky-Sommerer, R., David, J.P., Delacourte, A., Dournaud, P., and Epelbaum, J. (1998). Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci. Lett. 255, 21–24. CrossRef | PubMed

80-Gura, 2008 Gura, T. (2008). Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 14, 894. CrossRef | PubMed

81-Haan et al., 1999 Haan, M.N., Shemanski, L., Jagust, W.J., Manolio, T.A., and Kuller, L. (1999). The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282, 40–46. CrossRef | PubMed

82-Hampel et al., 2010 Hampel, H., Frank, R., Broich, K., Teipel, S.J., Katz, R.G., Hardy, J., Herholz, K., Bokde, A.L., Jessen, F., Hoessler, Y.C., et al. (2010). Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560–574. CrossRef | PubMed

83-Harris and Rubinsztein, 2011 Harris, H., and Rubinsztein, D.C. (2011). Control of autophagy as a therapy for neurodegenerative disease. Nat. Rev. Neurol. 8, 108–117. PubMed

84-Harris et al., 2003 Harris, F.M., Brecht, W.J., Xu, Q., Tesseur, I., Kekonius, L., Wyss-Coray, T., Fish, J.D., Masliah, E., Hopkins, P.C., Scearce-Levie, K., et al. (2003). Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc. Natl. Acad. Sci. USA 100, 10966–10971. CrossRef | PubMed

85-Harris et al., 2004 Harris, F.M., Tesseur, I., Brecht, W.J., Xu, Q., Mullendorff, K., Chang, S., Wyss-Coray, T., Mahley, R.W., and Huang, Y. (2004). Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J. Biol. Chem. 279, 3862–3868. CrossRef | PubMed

86-Harris et al., 2010 Harris, J.A., Devidze, N., Halabisky, B., Lo, I., Thwin, M.T., Yu, G.Q., Bredesen, D.E., Masliah, E., and Mucke, L. (2010). Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J. Neurosci. 30, 372–381. CrossRef | PubMed

87-Hartman et al., 2001 Hartman, R.E., Wozniak, D.F., Nardi, A., Olney, J.W., Sartorius, L., and Holtzman, D.M. (2001). Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp. Neurol. 170, 326–344. CrossRef | PubMed

88-Herrup, 2010 Herrup, K. (2010). Reimagining Alzheimer's disease—an age-based hypothesis. J. Neurosci. 30, 16755–16762. CrossRef | PubMed

89-Higashi et al., 2007 Higashi, S., Iseki, E., Yamamoto, R., Minegishi, M., Hino, H., Fujisawa, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., et al. (2007). Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 1184, 284–294. CrossRef | PubMed

90-Holtzman et al., 1995 Holtzman, D.M., Pitas, R.E., Kilbridge, J., Nathan, B., Mahley, R.W., Bu, G., and Schwartz, A.L. (1995). Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. USA 92, 9480–9484. CrossRef | PubMed

91-Holtzman et al., 1999 Holtzman, D.M., Bales, K.R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A.M., Chang, L.K., Sun, Y., and Paul, S.M. (1999). Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103, R15–R21. CrossRef | PubMed

92-Holtzman et al., 2000 Holtzman, D.M., Bales, K.R., Tenkova, T., Fagan, A.M., Parsadanian, M., Sartorius, L.J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97, 2892–2897. CrossRef | PubMed

93-Hoover et al., 2010 Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., Carlson, G.A., Lanier, L.M., Yuan, L.L., et al. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067–1081. Abstract | Full Text | PDF (2703 kb) | CrossRef | PubMed

94-Huang, 2006 Huang, Y. (2006). Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. Curr. Opin. Drug Discov. Devel. 9, 627–641. PubMed

95-Huang, 2010 Huang, Y. (2010). Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 16, 287–294. Abstract | Full Text | PDF (296 kb) | CrossRef | PubMed

96-Iqbal et al., 2010 Iqbal, K., Liu, F., Gong, C.X., and Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656–664. CrossRef | PubMed

97-Israel et al., 2012 Israel, M.A., Yuan, S.H., Bardy, C., Reyna, S.M., Mu, Y., Herrera, C., Hefferan, M.P., Van Gorp, S., Nazor, K.L., Boscolo, F.S., et al. (2012). Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216–220. PubMed

98-Ittner and Götz, 2011 Ittner, L.M., and Götz, J. (2011). Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12, 65–72. PubMed

99-Jack et al., 2011 Jack, C.R., Albert, M.S., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., Thies, B., and Phelps, C.H. (2011). Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 257–262. PubMed

100-Ji et al., 2002 Ji, Z.-S., Miranda, R.D., Newhouse, Y.M., Weisgraber, K.H., Huang, Y., and Mahley, R.W. (2002). Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. J. Biol. Chem. 277, 21821–21828. CrossRef | PubMed

101-Jo et al., 2011 Jo, J., Whitcomb, D.J., Olsen, K.M., Kerrigan, T.L., Lo, S.C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011). Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 14, 545–547. CrossRef | PubMed

102-Jones et al., 2011 Jones, P.B., Adams, K.W., Rozkalne, A., Spires-Jones, T.L., Hshieh, T.T., Hashimoto, T., von Armin, C.A., Mielke, M., Bacskai, B.J., and Hyman, B.T. (2011). Apolipoprotein E: Isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain. PLoS One 6, e14586. PubMed

103-Jucker, 2010 Jucker, M. (2010). The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat. Med. 16, 1210–1214. CrossRef | PubMed

104-Jucker and Walker, 2011 Jucker, M., and Walker, L.C. (2011). Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532–540. CrossRef | PubMed

105-Karran et al., 2011 Karran, E., Mercken, M., and De Strooper, B. (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698–712. CrossRef | PubMed

106-Kim et al., 2009 Kim, J., Basak, J.M., and Holtzman, D.M. (2009). The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287–303. Abstract | Full Text | PDF (652 kb) | CrossRef | PubMed

107-Kim et al., 2010 Kim, S., Jensen, J.R., Cisek, K., Funk, K.E., Naphade, S., Schafer, K., and Kuret, J. (2010). Imaging as a strategy for premortem diagnosis and staging of tauopathies. Curr. Alzheimer Res. 7, 230–234. CrossRef | PubMed

108-Kim et al., 2011 Kim, J., Jiang, H., Park, S., Eltorai, A.E., Stewart, F.R., Yoon, H., Basak, J.M., Finn, M.B., and Holtzman, D.M. (2011). Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31, 18007–18012. PubMed

109-Koh et al., 2010 Koh, M.T., Haberman, R.P., Foti, S., McCown, T.J., and Gallagher, M. (2010). Treatment strategies targeting excess hippocampal activity benefit aged rats with cognitive impairment. Neuropsychopharmacology 35, 1016–1025. CrossRef | PubMed

110-Koistinaho et al., 2004 Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K.R., et al. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat. Med. 10, 719–726. CrossRef | PubMed

111-Kramer et al., 2011 Kramer, P.L., Xu, H., Woltjer, R.L., Westaway, S.K., Clark, D., Erten-Lyons, D., Kaye, J.A., Welsh-Bohmer, K.A., Troncoso, J.C., Markesbery, W.R., et al. (2011). Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol. Aging 32, 2113–2122. CrossRef | PubMed

112-Lannfelt et al., 2008 Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C.L., Targum, S., Bush, A.I., Murdoch, R., et al.PBT2-201-EURO study group (2008). Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779–786. CrossRef | PubMed

113-Laskowitz et al., 2007 Laskowitz, D.T., McKenna, S.E., Song, P., Wang, H., Durham, L., Yeung, N., Christensen, D., and Vitek, M.P. (2007). COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J. Neurotrauma 24, 1093–1107. CrossRef | PubMed

114-Lee et al., 2010a Lee, H.P., Zhu, X., Casadesus, G., Castellani, R.J., Nunomura, A., Smith, M.A., Lee, H.G., and Perry, G. (2010). Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev. Neurother. 10, 1201–1208. CrossRef | PubMed

115-Lee et al., 2010b Lee, K.J., Moussa, C.E., Lee, Y., Sung, Y., Howell, B.W., Turner, R.S., Pak, D.T., and Hoe, H.S. (2010). Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience 169, 344–356. CrossRef | PubMed

116-Li et al., 2009 Li, G., Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Ring, K., Halabisky, B., Deng, C., Mahley, R.W., and Huang, Y. (2009). GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell 5, 634–645. PubMed

117-Li et al., 2011 Li, S., Jin, M., Koeglsperger, T., Shepardson, N.E., Shankar, G.M., and Selkoe, D.J. (2011). Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 6627–6638. CrossRef | PubMed

118-Logue et al., 2011 Logue, M.W., Schu, M., Vardarajan, B.N., Buros, J., Green, R.C., Go, R.C., Griffith, P., Obisesan, T.O., Shatz, R., Borenstein, A., et al.Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (2011). A comprehensive genetic association study of Alzheimer disease in African Americans. Arch. Neurol. 68, 1569–1579. PubMed

119-Lopez et al., 2009 Lopez, O.L., Becker, J.T., Wahed, A.S., Saxton, J., Sweet, R.A., Wolk, D.A., Klunk, W., and Dekosky, S.T. (2009). Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80, 600–607. CrossRef | PubMed

120-Mahley et al., 2006 Mahley, R.W., Weisgraber, K.H., and Huang, Y. (2006). Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 5644–5651. CrossRef | PubMed

121-Marchetti and Marie, 2011 Marchetti, C., and Marie, H. (2011). Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models?. Rev. Neurosci. 22, 373–402. CrossRef | PubMed

122-Masliah et al., 1995 Masliah, E., Mallory, M., Ge, N., Alford, M., Veinbergs, I., and Roses, A.D. (1995). Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136, 107–122. CrossRef | PubMed

123-Masliah et al., 2001 Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., and Mucke, L. (2001). β-amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 12245–12250. CrossRef | PubMed

124-Masliah et al., 2005 Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005). Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857–868. Abstract | Full Text | PDF (792 kb) | CrossRef | PubMed

125-Mawuenyega et al., 2010 Mawuenyega, K.G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J.C., Yarasheski, K.E., and Bateman, R.J. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774. CrossRef | PubMed

126-Meilandt et al., 2008 Meilandt, W.J., Yu, G.-Q., Chin, J., Roberson, E.D., Palop, J.J., Wu, T., Scearce-Levie, K., and Mucke, L. (2008). Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 28, 5007–5017. CrossRef | PubMed

127-Millan Sanchez et al., 2011 Millan Sanchez, M., Heyn, S.N., Das, D., Moghadam, S., Martin, K.J., and Salehi, A. (2011). Neurobiological elements of cognitive dysfunction in Down Syndrome: Exploring the role of APP. Biol. Psychiatry 71, 403–409. CrossRef | PubMed

128-Miller et al., 2010 Miller, J.A., Horvath, S., and Geschwind, D.H. (2010). Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways. Proc. Natl. Acad. Sci. USA 107, 12698–12703. CrossRef | PubMed

129-Miller et al., 2011 Miller, J., Arrasate, M., Brooks, E., Libeu, C.P., Legleiter, J., Hatters, D., Curtis, J., Cheung, K., Krishnan, P., Mitra, S., et al. (2011). Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat. Chem. Biol. 7, 925–934. CrossRef | PubMed

130-Min et al., 2010 Min, S.W., Cho, S.H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W.W., Huang, E.J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010). Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953–966. Abstract | Full Text | PDF (1696 kb) | CrossRef | PubMed

131-Morris et al., 2009 Morris, J.C., Roe, C.M., Grant, E.A., Head, D., Storandt, M., Goate, A.M., Fagan, A.M., Holtzman, D.M., and Mintun, M.A. (2009). Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66, 1469–1475. CrossRef | PubMed

132-Morris et al., 2011 Morris, M., Maeda, S., Vossel, K., and Mucke, L. (2011). The many faces of tau. Neuron 70, 410–426. Abstract | Full Text | PDF (943 kb) | CrossRef | PubMed

133-Nixon and Yang, 2011 Nixon, R.A., and Yang, D.S. (2011). Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol. Dis. 43, 38–45. CrossRef | PubMed

134-Palop and Mucke, 2009 Palop, J.J., and Mucke, L. (2009). Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 66, 435–440. CrossRef | PubMed

135-Palop and Mucke, 2010 Palop, J.J., and Mucke, L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812–818. CrossRef | PubMed

136-Palop et al., 2003 Palop, J.J., Jones, B., Kekonius, L., Chin, J., Yu, G.-Q., Raber, J., Masliah, E., and Mucke, L. (2003). Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA 100, 9572–9577. CrossRef | PubMed

137-Palop et al., 2006 Palop, J.J., Chin, J., and Mucke, L. (2006). A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768–773. CrossRef | PubMed

138-Peleg et al., 2010 Peleg, S., Sananbenesi, F., Zovoilis, A., Burkhardt, S., Bahari-Javan, S., Agis-Balboa, R.C., Cota, P., Wittnam, J.L., Gogol-Doering, A., Opitz, L., et al. (2010). Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753–756. CrossRef | PubMed

139-Perry et al., 2010 Perry, V.H., Nicoll, J.A., and Holmes, C. (2010). Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6, 193–201. PubMed

140-Pickford et al., 2008 Pickford, F., Masliah, E., Britschgi, M., Lucin, K., Narasimhan, R., Jaeger, P.A., Small, S., Spencer, B., Rockenstein, E., Levine, B., et al. (2008). The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 118, 2190–2199. PubMed

141-Prasher et al., 1998 Prasher, V.P., Farrer, M.J., Kessling, A.M., Fisher, E.M.C., West, R.J., Barber, P.C., and Butler, A.C. (1998). Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43, 380–383. CrossRef | PubMed

142-Putcha et al., 2011 Putcha, D., Brickhouse, M., O'Keefe, K., Sullivan, C., Rentz, D., Marshall, G., Dickerson, B., and Sperling, R. (2011). Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J. Neurosci. 31, 17680–17688. PubMed

143-Puzzo et al., 2011 Puzzo, D., Privitera, L., Fa', M., Staniszewski, A., Hashimoto, G., Aziz, F., Sakurai, M., Ribe, E.M., Troy, C.M., Mercken, M., et al. (2011). Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann. Neurol. 69, 819–830. CrossRef | PubMed

144-Querfurth and LaFerla, 2010 Querfurth, H.W., and LaFerla, F.M. (2010). Alzheimer's disease. N. Engl. J. Med. 362, 329–344. CrossRef | PubMed

145-Raber et al., 1998 Raber, J., Wong, D., Buttini, M., Orth, M., Bellosta, S., Pitas, R.E., Mahley, R.W., and Mucke, L. (1998). Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. USA 95, 10914–10919. CrossRef | PubMed

146-Raber et al., 2000 Raber, J., Wong, D., Yu, G.-Q., Buttini, M., Mahley, R.W., Pitas, R.E., and Mucke, L. (2000). Apolipoprotein E and cognitive performance. Nature 404, 352–354. CrossRef | PubMed

147-Raber et al., 2002 Raber, J., Bongers, G., LeFevour, A., Buttini, M., and Mucke, L. (2002). Androgens protect against apolipoprotein E4-induced cognitive deficits. J. Neurosci. 22, 5204–5209. PubMed

148-Reddy et al., 2011 Reddy, M.M., Wilson, R., Wilson, J., Connell, S., Gocke, A., Hynan, L., German, D., and Kodadek, T. (2011). Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell 144, 132–142. Abstract | Full Text | PDF (1233 kb) | CrossRef | PubMed

149-Reiman et al., 2011 Reiman, E.M., Langbaum, J.B., Fleisher, A.S., Caselli, R.J., Chen, K., Ayutyanont, N., Quiroz, Y.T., Kosik, K.S., Lopera, F., and Tariot, P.N. (2011). Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26, (Suppl 3) 321–329. PubMed

150-Remes et al., 2008 Remes, A.M., Laru, L., Tuominen, H., Aalto, S., Kemppainen, N., Mononen, H., Någren, K., Parkkola, R., and Rinne, J.O. (2008). Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch. Neurol. 65, 540–544. CrossRef | PubMed

151-Renner et al., 2010 Renner, M., Lacor, P.N., Velasco, P.T., Xu, J., Contractor, A., Klein, W.L., and Triller, A. (2010). Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739–754. Abstract | Full Text | PDF (1623 kb) | CrossRef | PubMed

152-Riddell et al., 2008 Riddell, D.R., Zhou, H., Atchison, K., Warwick, H.K., Atkinson, P.J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008). Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28, 11445–11453. CrossRef | PubMed

153-Rönicke et al., 2011 Rönicke, R., Mikhaylova, M., Rönicke, S., Meinhardt, J., Schröder, U.H., Fändrich, M., Reiser, G., Kreutz, M.R., and Reymann, K.G. (2011). Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol. Aging 32, 2219–2228. CrossRef | PubMed

154-Rosendorff et al., 2007 Rosendorff, C., Beeri, M.S., and Silverman, J.M. (2007). Cardiovascular risk factors for Alzheimer's disease. Am. J. Geriatr. Cardiol. 16, 143–149. CrossRef | PubMed

155-Rovelet-Lecrux et al., 2006 Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006). APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24–26. CrossRef | PubMed

156-Sadowski et al., 2006 Sadowski, M.J., Pankiewicz, J., Scholtzova, H., Mehta, P.D., Prelli, F., Quartermain, D., and Wisniewski, T. (2006). Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103, 18787–18792. CrossRef | PubMed

157-Sahara et al., 2005 Sahara, N., Murayama, M., Mizoroki, T., Urushitani, M., Imai, Y., Takahashi, R., Murata, S., Tanaka, K., and Takashima, A. (2005). In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 94, 1254–1263. CrossRef | PubMed

158-Sahara et al., 2007 Sahara, N., Maeda, S., Yoshiike, Y., Mizoroki, T., Yamashita, S., Murayama, M., Park, J.M., Saito, Y., Murayama, S., and Takashima, A. (2007). Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain. J. Neurosci. Res. 85, 3098–3108. CrossRef | PubMed

159-Salloway et al., 2009 Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L.S., Doody, R., van Dyck, C.H., et al.Bapineuzumab 201 Clinical Trial Investigators (2009). A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061–2070. CrossRef | PubMed

160-Salloway et al., 2011 Salloway, S., Sperling, R., Keren, R., Porsteinsson, A.P., van Dyck, C.H., Tariot, P.N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al.ELND005-AD201 Investigators (2011). A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77, 1253–1262. CrossRef | PubMed

161-Sanchez-Mejia et al., 2008 Sanchez-Mejia, R.O., Newman, J.W., Toh, S., Yu, G.Q., Zhou, Y., Halabisky, B., Cissé, M., Scearce-Levie, K., Cheng, I.H., Gan, L., et al. (2008). Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 11, 1311–1318. CrossRef | PubMed

162-Sarantseva et al., 2009 Sarantseva, S., Timoshenko, S., Bolshakova, O., Karaseva, E., Rodin, D., Schwarzman, A.L., and Vitek, M.P. (2009). Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. PLoS ONE 4, e8191. PubMed

163-Sastre et al., 2011 Sastre, M., Richardson, J.C., Gentleman, S.M., and Brooks, D.J. (2011). Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr. Alzheimer Res. 8, 132–141. PubMed

164-Schenk et al., 1999 Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999). Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177. CrossRef | PubMed

165-Schirmer et al., 2011 Schirmer, R.H., Adler, H., Pickhardt, M., and Mandelkow, E. (2011). “Lest we forget you—methylene blue…”. Neurobiol. Aging 32, , 2325, e7–e16. PubMed

166-Schor, 2011 Schor, N.F. (2011). What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us. Ann. Neurol. 69, 237–239. CrossRef | PubMed

167-Sharp and Gatz, 2011 Sharp, E.S., and Gatz, M. (2011). Relationship between education and dementia: an updated systematic review. Alzheimer Dis. Assoc. Disord. 25, 289–304. CrossRef | PubMed

168-Shaw et al., 2007 Shaw, P., Lerch, J.P., Pruessner, J.C., Taylor, K.N., Rose, A.B., Greenstein, D., Clasen, L., Evans, A., Rapoport, J.L., and Giedd, J.N. (2007). Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 6, 494–500. CrossRef | PubMed

169-Sheng and Cai, 2012 Sheng, Z.H., and Cai, Q. (2012). Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 13, 77–93. PubMed

170-Shimada et al., 2011 Shimada, H., Ataka, S., Tomiyama, T., Takechi, H., Mori, H., and Miki, T. (2011). Clinical course of patients with familial early-onset Alzheimer's disease potentially lacking senile plaques bearing the E693Delta mutation in amyloid precursor protein. Dement. Geriatr. Cogn. Disord. 32, 45–54. CrossRef | PubMed

171-Shineman et al., 2011 Shineman, D.W., Basi, G.S., Bizon, J.L., Colton, C.A., Greenberg, B.D., Hollister, B.A., Lincecum, J., Leblanc, G.G., Lee, L.B., Luo, F., et al. (2011). Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res. Ther. 3, 28. PubMed

172-Shumaker et al., 2003 Shumaker, S.A., Legault, C., Rapp, S.R., Thal, L., Wallace, R.B., Ockene, J.K., Hendrix, S.L., Jones, B.N., Assaf, A.R., Jackson, R.D., et al.WHIMS Investigators (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2651–2662. CrossRef | PubMed

173-Sigurdsson, 2009 Sigurdsson, E.M. (2009). Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr. Alzheimer Res. 6, 446–450. CrossRef | PubMed

174-Simón et al., 2009 Simón, A.M., Schiapparelli, L., Salazar-Colocho, P., Cuadrado-Tejedor, M., Escribano, L., López de Maturana, R., Del Río, J., Pérez-Mediavilla, A., and Frechilla, D. (2009). Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol. Dis. 33, 369–378. CrossRef | PubMed

175-Small et al., 2000 Small, G.W., Ercoli, L.M., Silverman, D.H.S., Huang, S.C., Komo, S., Bookheimer, S.Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N.L., et al. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97, 6037–6042. CrossRef | PubMed

176-Sperling et al., 2010 Sperling, R.A., Dickerson, B.C., Pihlajamaki, M., Vannini, P., LaViolette, P.S., Vitolo, O.V., Hedden, T., Becker, J.A., Rentz, D.M., Selkoe, D.J., et al. (2010). Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 12, 27–43. CrossRef | PubMed

177-Sperling et al., 2011b Sperling, R.A., Jack, C.R., Black, S.E., Frosch, M.P., Greenberg, S.M., Hyman, B.T., Scheltens, P., Carrillo, M.C., Thies, W., Bednar, M.M., et al. (2011). Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367–385. PubMed

178-Srikanth et al., 2011 Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., and Münch, G. (2011). Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol. Aging 32, 763–777. CrossRef | PubMed

179-Taniguchi et al., 2005 Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., and Hasegawa, M. (2005). Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614–7623. CrossRef | PubMed

180-Tomiyama et al., 2010 Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010). A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 30, 4845–4856. CrossRef | PubMed

181-Van Den Heuvel et al., 2007 Van Den Heuvel, C., Thornton, E., and Vink, R. (2007). Traumatic brain injury and Alzheimer's disease: a review. Prog. Brain Res. 161, 303–316. CrossRef | PubMed

182-Vepsäläinen et al., 2007 Vepsäläinen, S., Helisalmi, S., Koivisto, A.M., Tapaninen, T., Hiltunen, M., and Soininen, H. (2007). Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients. J. Neurol. 254, 1504–1508. CrossRef | PubMed

183-Verret et al., 2012 Verret, L., Mann, E.O., Hang, G.B., Barth, A.M.I., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A.C., Mody, I., et al. (2012). Key role of interneuronal impairments in Alzheimer's disease-related neural network and cognitive dysfunction. Cell 149, , doi:10.1016/j.cell.2012.02.046 | Published online April 26, 2012. PubMed

184-Villeda et al., 2011 Villeda, S.A., Luo, J., Mosher, K.I., Zou, B., Britschgi, M., Bieri, G., Stan, T.M., Fainberg, N., Ding, Z., Eggel, A., et al. (2011). The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90–94. CrossRef | PubMed

185-Villemagne et al., 2009 Villemagne, V.L., Ataka, S., Mizuno, T., Brooks, W.S., Wada, Y., Kondo, M., Jones, G., Watanabe, Y., Mulligan, R., Nakagawa, M., et al. (2009). High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 66, 1537–1544. CrossRef | PubMed

186-Vossel et al., 2010 Vossel, K.A., Zhang, K., Brodbeck, J., Daub, A.C., Sharma, P., Finkbeiner, S., Cui, B., and Mucke, L. (2010). Tau reduction prevents Abeta-induced defects in axonal transport. Science 330, 198. CrossRef | PubMed

187-Vossel et al., 2012 Vossel, K., Bien-Ly, N., Bernardo, A., Rascovsky, K., Karydas, A., Rabinovici, G., Sidhu, M., Huang, E., Miller, B., Huang, Y., et al. (2012). ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease. Neurocase . doi:10.1080/13554794.2012.667124 | PubMed

188-Vulih-Shultzman et al., 2007 Vulih-Shultzman, I., Pinhasov, A., Mandel, S., Grigoriadis, N., Touloumi, O., Pittel, Z., and Gozes, I. (2007). Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 323, 438–449. CrossRef | PubMed

189-Weyer et al., 2011 Weyer, S.W., Klevanski, M., Delekate, A., Voikar, V., Aydin, D., Hick, M., Filippov, M., Drost, N., Schaller, K.L., Saar, M., et al. (2011). APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP. EMBO J. 30, 2266–2280. CrossRef | PubMed

190-Wimo and Prince, 2010 Wimo, A., and Prince, M. (2010). World Alzheimer Report 2010: The Global Economic Impact of Dementia. (London: Alzheimer's Disease International), pp. 1–56. PubMed

191-Winner et al., 2011 Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194–4199. CrossRef | PubMed

192-Wu et al., 2011 Wu, J., Petralia, R.S., Kurushima, H., Patel, H., Jung, M.Y., Volk, L., Chowdhury, S., Shepherd, J.D., Dehoff, M., Li, Y., et al. (2011). Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell 147, 615–628. Abstract | Full Text | PDF (2651 kb) | CrossRef | PubMed

193-Xu et al., 2006 Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R.W., and Huang, Y. (2006). Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26, 4985–4994. CrossRef | PubMed

194-Xu et al., 2008 Xu, Q., Walker, D., Bernardo, A., Brodbeck, J., Balestra, M.E., and Huang, Y. (2008). Intron-3 retention/splicing controls neuronal expression of apolipoprotein E in the CNS. J. Neurosci. 28, 1452–1459. CrossRef | PubMed

195-Yang et al., 2009 Yang, L., Wang, Z., Wang, B., Justice, N.J., and Zheng, H. (2009). Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. J. Neurosci. 29, 15660–15668. CrossRef | PubMed

196-Yang et al., 2011a Yang, D.S., Stavrides, P., Mohan, P.S., Kaushik, S., Kumar, A., Ohno, M., Schmidt, S.D., Wesson, D.W., Bandyopadhyay, U., Jiang, Y., et al. (2011). Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy 7, 788–789. CrossRef | PubMed

197-Yang et al., 2011b Yang, J., Ji, Y., Mehta, P., Bates, K.A., Sun, Y., and Wisniewski, T. (2011). Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J. Alzheimers Dis. 24, 269–285. PubMed

198-Ye et al., 2005 Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E.C., Cohen, F.E., Kuntz, I.D., Weisgraber, K.H., and Mahley, R.W. (2005). Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. USA 102, 18700–18705. CrossRef | PubMed

199-Zahs and Ashe, 2010 Zahs, K.R., and Ashe, K.H. (2010). ‘Too much good news’ - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?. Trends Neurosci. 33, 381–389. Abstract | Full Text | PDF (390 kb) | CrossRef | PubMed

200-Zempel et al., 2010 Zempel, H., Thies, E., Mandelkow, E., and Mandelkow, E.M. (2010). Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30, 11938–11950. CrossRef | PubMed

201-Zhang et al., 2005 Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E.B., Xie, S.X., Joyce, S., Li, C., et al. (2005). Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl. Acad. Sci. USA 102, 227–231. CrossRef | PubMed

202-Zhong and Weisgraber, 2009 Zhong, N., and Weisgraber, K.H. (2009). Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J. Biol. Chem. 284, 6027–6031. CrossRef | PubMed

 

 

 

 

************************
Autori: Yadong Huang & Lennart Mucke, Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA & Dipartimento di Neurologia, Università di California, San Francisco, CA 94158, USA

Fonte:
Cell (> English text) - Traduzione di Franco Pellizzari - Scarica il file originale in .pdf - in Inglese

Riferimenti: Yadong Huang, Lennart Mucke. Alzheimer Mechanisms and Therapeutic Strategies. Cell, Volume 148, Issue 6, 1204-1222, 16 March 2012, doi:10.1016/j.cell.2012.02.040. Copyright © 2012 Elsevier Inc. All rights reserved.

Copyright: Tutti i diritti di eventuali testi o marchi citati nell'articolo sono riservati ai rispettivi proprietari.

Liberatoria: Questo articolo non propone terapie o diete; per qualsiasi modifica della propria cura o regime alimentare si consiglia di rivolgersi a un medico o dietologo. Il contenuto non dipende da, nè impegna l'Associazione Alzheimer onlus di Riese Pio X. I siti terzi raggiungibili da eventuali links contenuti nell'articolo e/o dagli annunci pubblicitari proposti da Google sono completamente estranei all'Associazione, il loro accesso e uso è a discrezione dell'utente. Liberatoria completa qui.

Nota: L'articolo potrebbe riferire risultati di ricerche mediche, psicologiche, scientifiche o sportive che riflettono lo stato delle conoscenze raggiunte fino alla data della loro pubblicazione.

Sostieni l'Associazione; una donazione, anche minima, ci aiuterà ad assistere malati e famiglie e continuare ad informarti. Clicca qui a destra:

Annuncio pubblicitario

NOTA! Questo sito utilizza i cookie e tecnologie simili.

Se non si modificano le impostazioni del browser, l'utente accetta. Per saperne di piu'

Approvo

Privacy e sicurezza dati - Informativa ex Art. 13 D. Lgs. 196/03

Gentile visitatore,

l'Associazione tratterà i Tuoi dati personali nel rispetto del D. Lgs. 196/G3 (Codice della privacy), garantendo la riservatezza e la protezione dei dati.

Finalità e modalità del trattamento: I dati personali che volontariamente deciderai di comunicarci, saranno utilizzati esclusivamente per le attività del sito, per la gestione del rapporto associativo e per l'adempimento degli obblighi di legge. I trattamenti dei dati saranno svolti in forma cartacea e mediante computer, con adozione delle misure di sicurezza previste dalla legge. I dati non saranno comunicati a terzi né saranno diffusi.

Dati sensibili: Il trattamento di dati sensibili ex art. 1, lett. d del Codice sarà effettuato nei limiti di cui alle autorizzazioni del Garante n. 2/08 e n. 3/08, e loro successive modifiche.

Diritti dell'interessata/o: Nella qualità di interessato, Ti sono garantiti tutti i diritti specificati all'art. 7 del Codice, tra cui il diritto di chiedere e ottenere l'aggiornamento, la rettificazione o l'integrazione dei dati, la cancellazione, la trasformazione in forma anonima o il blocco dei dati trattati in violazione di legge, e il diritto di opporsi, in tutto o in parte, per motivi legittimi, al trattamento dei dati personali che Ti riguardano.

Titolare del trattamento è l'Associazione di volontariato "Associazione Alzheimer o.n.l.u.s.”, con sede a Riese Pio X – Via Schiavonesca, 13 – telefax 0423 750 324.

Responsabile del trattamento è la segretaria dell’Associazione in carica.

Gestione «cookies»

Un cookie è una breve stringa di testo che il sito web che si sta visitando salva automaticamente sul computer dell'utente. I cookies sono utilizzati dagli amministratori di molti siti web per migliorarne funzionamento ed efficienza e per raccogliere dati sui visitatori.

Il nostro sito non utilizza i cookies per identificare i visitatori, ma per raccogliere informazioni al fine di arricchirne i contenuti e rendere il sito più fruibile.

Come cambiare le impostazioni del browser per la gestione dei cookies

È possibile decidere se permettere ai siti web che vengono visitati di installare i cookies modificando le impostazioni del browser usato per la navigazione. Se hai già visitato il nostro sito, alcuni cookies potrebbero essere già stati impostati automaticamente sul tuo computer. Per sapere come eliminarli, clicca su uno dei link qui di seguito: